A lipid-lowering drug once described as a potential blockbuster has failed to meet its primary endpoint in a phase 3 trial, a result that shocked much of the cardiology community and the roughly 1.4 billion people behind the risk it targets.
On November 3, the journal Nature published a feature asking whether the target still has hope. In early September, the pharmaceutical company Novartis announced that pelacarsen, its drug for treating elevated lipoprotein(a) [Lp(a)], had failed in a phase 3 trial to reduce cardiovascular event outcomes, including cardiovascular death and non-fatal myocardial infarction.
Lp(a) is a lipoprotein particle in the blood that deposits on vessel walls and promotes the formation of atherosclerosis. It is an independent risk factor for cardiovascular events. To date, no drug anywhere in the world specifically treats elevated Lp(a).
Earlier, the phase 2 trial of pelacarsen showed that it could lower Lp(a) levels by as much as 80%. All it then needed to show was that this “lowering” ultimately translated into health benefit for patients, which would have changed the “rules of the game” entirely.
But it has now failed. “When I saw the result I was very surprised; I genuinely did not expect a negative outcome,” said Dr. Zhenyue Chen, chief physician of the Department of Cardiology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, in an interview with MedJ. “But I do not think this road ends here. We still need to see the specific data released later, and the phase 3 results of the other several drugs.”
Article Key Points
- Lp(a)HORIZON enrolled 8,323 patients with established cardiovascular disease and Lp(a) ≥70 mg/dL
- Pelacarsen lowered Lp(a) versus placebo but did not reduce cardiovascular events in the overall population
- The primary endpoint combined cardiovascular death, myocardial infarction, stroke, and urgent revascularisation
- Phase 2 pelacarsen lowered Lp(a) by up to 80%; the siRNA agents lowered it by more than 90%
- Proposed explanations include controlled LDL at baseline, follow-up of 4-5 years, and intervention after disease onset
- Chinese guidelines set 30 mg/dL and above as the threshold for elevated Lp(a) with increased cardiovascular risk
- Dr. Chen believes it is too early to abandon the target, and that trial design should be optimised
- Olpasiran and lepodisiran remain investigational; no Lp(a)-lowering drug is approved for this indication
The Expectations of 1.4 Billion People
Related statistics indicate that approximately 1.4 billion people worldwide, including as many as 280 million in China, have elevated Lp(a) levels in their blood, which greatly increases their risk of cardiovascular and cerebrovascular events such as myocardial infarction and stroke, as well as all-cause mortality.
In clinical practice, Dr. Chen told MedJ, she often encounters younger patients whose cardiovascular markers are all normal except Lp(a), yet who have developed arterial plaques, coronary heart disease, calcific aortic valve stenosis, or other clinical conditions. Elevated Lp(a) may be a key cause among them.
“Lp(a) has attracted growing attention from both the research community and patients, roughly from three or four years ago,” Dr. Chen told MedJ. “The main reason is that many doctors have found that some patients still experienced major cardiovascular events even though their risk factors, such as low-density lipoprotein cholesterol (LDL-C), were well controlled.”
“Lp(a) levels differ across countries and ethnic groups, and so do the risk thresholds for cardiovascular disease,” Dr. Chen told MedJ. “At present, the threshold recommended by Chinese guidelines is 30 mg/dL and above, which defines elevated Lp(a) with increased cardiovascular risk. According to a study published in 2024, the effect of Lp(a) on atherosclerosis is about 6.6 times that of LDL.”
More importantly, elevated Lp(a) is highly correlated with genetic factors. There is currently no targeted drug for it, and for most patients it is difficult to lower Lp(a) levels through lifestyle measures such as exercise and diet.
For exactly this reason, investigational Lp(a)-lowering drugs such as pelacarsen have been held in high hopes by the global research community and by patients. Pelacarsen is an antisense oligonucleotide (ASO) drug that reduces Lp(a) production at its source through an effect similar to “gene silencing,” and thereby lowers Lp(a) levels in the blood.
In 2020, the phase 2 results of pelacarsen were published in the New England Journal of Medicine. Among 286 patients with confirmed cardiovascular disease and elevated Lp(a) levels, pelacarsen lowered Lp(a) by as much as about 80%, with a favourable safety profile.
A reduction of that magnitude was unprecedented. After that, small interfering RNA (siRNA) drugs such as olpasiran from Amgen and lepodisiran from Eli Lilly followed, and likewise showed excellent efficacy, lowering Lp(a) by more than 90% in clinical trials.
“Results like these mean that the development of Lp(a)-lowering drugs has already reached the limit in terms of lowering the marker, and is only one step short,” Dr. Chen said. Researchers now only need to demonstrate that when a patient’s Lp(a) falls, health outcomes improve, for example fewer cardiac-related deaths, heart attacks, or strokes.
“If that were achieved, a range of cardiovascular clinical practices, from testing and diagnostic and treatment guidelines to combination therapy and long-term chronic disease management, could all change, and it would be revolutionary for the prevention and treatment of cardiovascular disease,” Dr. Chen said.
Where Did the Problem Occur?
“I had absolutely no expectation that the result would be like this,” Dr. Chen told MedJ.
The phase 3 study of pelacarsen enrolled 8,323 patients with confirmed cardiovascular disease and Lp(a) levels of ≥70 mg/dL. According to the press release Novartis issued on September 4, although Lp(a) levels fell in treated patients, this did not translate into a reduction in overall cardiovascular risk in the study population compared with placebo.
The complete phase 3 data for pelacarsen have not yet been released. On the possible reasons for the failure, Børge Nordestgaard, president of the European Atherosclerosis Society, told Nature that this may be because LDL levels in the enrolled patients were already controlled, offsetting the benefit of further Lp(a) reduction.
Dr. Chen explained further to MedJ that LDL, intermediate-density lipoprotein, very-low-density lipoprotein, and other such particles in the blood all drive atherosclerosis, of which LDL accounts for the largest share, with Lp(a) representing only a small part.
“The patients enrolled in this study were those whose ‘largest component’ was already under control,” Dr. Chen analysed. The trial population was not one in which elevated Lp(a) alone drove cardiovascular disease, and other risk factors were also present. “Before they received pelacarsen, their other indicators were already well controlled. On that basis, even a significant reduction in Lp(a) may not have brought additional benefit over 4-5 years of follow-up.”
Time may be another key variable. Lp(a) levels are determined mainly by genetics, and people with high Lp(a) have been exposed to this risk from birth, with vascular damage accumulating over decades.
Prof. Roger S. Blumenthal of cardiology at Johns Hopkins University School of Medicine in the United States argued that participants received pelacarsen injections once a month for only several years, and that “perhaps four or five years is not enough.”
At the same time, “the participants in this study all had confirmed cardiovascular disease, which amounts to intervening only after the disease has already occurred. Whether risk can be reversed at this stage by lowering Lp(a) is also something that has to be questioned,” Dr. Chen analysed.
Regardless of the cause, this failure has led the research community to reconsider the Lp(a) target as a whole: if a drug that lowers Lp(a) by more than 80% cannot bring benefit, can other similar drugs succeed?
Does It Still Have Hope?
Besides pelacarsen from Novartis, other Lp(a)-lowering drugs in development that are progressing relatively quickly include olpasiran from Amgen and lepodisiran from Eli Lilly.
Olpasiran is in a phase 3 study enrolling more than 7,000 patients, with primary endpoint data expected to be collected by the end of 2026. The phase 3 study of lepodisiran recruited approximately 12,500 patients, covering both patients with confirmed cardiovascular disease and high-risk primary prevention populations, and is expected to complete in 2029.
As the first drug to report cardiovascular outcome data, the failure of the pelacarsen study has undoubtedly cast a shadow over those that follow.
George Thanassoulis, associate professor of medicine at McGill University in Canada, stated plainly that the chances of pelacarsen gaining marketing approval are now small. Some analysts have also pointed out that this failure has raised the “burden of proof” for subsequent drugs, which will need more convincing data.
This does not, however, mean that the Lp(a) target has been definitively declared a failure. Dr. Chen believes it is too early to draw that conclusion.
“From the standpoint of the target itself, the relationship between Lp(a) and cardiovascular disease rests on solid evidence,”Dr. Chen said. “Genetic and epidemiological studies both show that people with inherently high Lp(a) levels have a markedly higher risk of cardiovascular disease, which indicates that Lp(a) is likely a cause of the disease rather than merely a marker that accompanies it.”
The key to the next step may lie in further optimising trial design and identifying populations that benefit.
“The baseline characteristics of the patients enrolled in the studies now under way differ from one another. Some set higher enrolment thresholds, while others simultaneously include lower-risk primary prevention populations. Only by placing the results of several key studies together can the overall effect of lowering Lp(a) be judged,” Dr. Chen said.
“If most of the subsequent studies are also negative, then the future development of Lp(a)-lowering drugs may need to focus on populations in whom elevated Lp(a) is the dominant risk. For the development of a new target, this may be a necessary stage in the process,” Dr. Chen said.
The complete phase 3 data for pelacarsen are due to be presented at the American Heart Association (AHA) Annual Meeting in the near future. “Only once the complete results are published will we be able to see more detail on the Lp(a) level subgroups and secondary endpoints, and further analyse the reasons the primary endpoint was missed,” Dr. Chen said.
Dr. Chen also cautioned that because no effective treatment is currently available, people with high Lp(a) need to control other cardiovascular risk factors as far as possible.
“Even though Lp(a) cannot yet be lowered, controlling other risk factors such as cholesterol, blood pressure, and blood glucose through drug treatment or lifestyle intervention can partly offset the disease risk that Lp(a) carries. In the management of these other indicators, people with elevated Lp(a) may need to reach levels stricter than those of the general population,” Dr. Chen said.